Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs INNOHEP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients at risk for thromboembolic complications,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) with aspirin,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism (FDA-approved),Prophylaxis of venous thromboembolism in patients undergoing hip replacement surgery,Prophylaxis of venous thromboembolism in patients undergoing knee replacement surgery,Prophylaxis of venous thromboembolism in abdominal surgery
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (Cr Cl <30 m L/min).
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Enoxaparin is primarily metabolized in the liver via desulfation and depolymerization, with some renal clearance. It does not rely on cytochrome P450 enzymes.
Tinzaparin is primarily metabolized in the liver via desulfation and depolymerization, with some involvement of renal excretion of lower molecular weight fragments.
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Approximately 92-95% bound to antithrombin III (ATIII) and other plasma proteins.
90% bound to antithrombin III.
0.10-0.13 L/kg; confined primarily to intravascular space, indicating limited extravascular distribution.
0.15-0.25 L/kg; reflects limited extravascular distribution consistent with high protein binding.
Subcutaneous: Approximately 92-100% absorbed; intravenous administration yields 100% bioavailability.
Subcutaneous: 90-100%.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis: 30 mg subcutaneously once daily. Not recommended if Cr Cl <15 m L/min.
For Cr Cl 30-50 m L/min: dose reduction by 25%; Cr Cl <30 m L/min: dose reduction by 50% and monitor anti-Xa activity. Alternative: avoid use if Cr Cl <30 m L/min.
No specific dose adjustment guidelines for hepatic impairment; use with caution in severe hepatic impairment due to increased bleeding risk.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: contraindicated.
Dose based on age: neonates and infants <2 months: 1.5 mg/kg subcutaneously every 12 hours; children ≥2 months: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours.
Not recommended for use in children due to lack of safety and efficacy data. Consider alternative low molecular weight heparins with established pediatric dosing.
Increased risk of bleeding, especially in elderly ≥75 years; consider dose reduction and monitor renal function and anti-Xa levels. For treatment in elderly ≥75 years: 1 mg/kg subcutaneously every 12 hours; no routine dose reduction but caution advised.
Elderly patients (age ≥75 years) may have reduced renal function; dose should be based on renal function (see renal adjustment). Caution as increased risk of bleeding, especially with body weight <45 kg. Consider anti-Xa monitoring.
Spinal/epidural hematomas may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis. Risk is increased by use of indwelling epidural catheters, concomitant use of other anticoagulants, or history of spinal surgery/deformity. Monitor for signs of neurological impairment and manage emergently.
Epidural or spinal hematomas may occur in patients anticoagulated with low molecular weight heparins or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider monitoring for signs and symptoms of neurological impairment and urgent treatment if suspected.
Risk of spinal/epidural hematoma with neuraxial procedures,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or concurrent use of anticoagulants/antiplatelets,Heparin-induced thrombocytopenia (HIT) possible; monitor platelet counts,Use with caution in patients with bleeding disorders, uncontrolled hypertension, or recent surgery,Not interchangeable with other heparins (unit-for-unit)
Risk of hemorrhage: monitor for signs of bleeding,Thrombocytopenia: risk of heparin-induced thrombocytopenia (HIT),Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) as exposure may be increased,Do not administer intramuscularly due to risk of hematoma,Monitor anti-factor Xa activity in patients with severe renal impairment, obesity, or during pregnancy
Active major bleeding,History of immune-mediated heparin-induced thrombocytopenia (HIT) within 100 days,Known hypersensitivity to enoxaparin, heparin, or pork products,Concomitant use with other anticoagulants (except under close monitoring)
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT),Active major bleeding,Known hypersensitivity to tinzaparin, heparin, or pork products,Concurrent use of neuraxial anesthesia or spinal puncture (relative; requires caution),Severe uncontrolled hypertension
No specific food restrictions. Avoid excessive consumption of alcohol (may increase bleeding risk). Maintain adequate vitamin K intake, but avoid sudden large changes.
No specific food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if also on warfarin; not required with Innohep alone. Limit alcohol intake as it may increase bleeding risk.
Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no known teratogenic effects. Second trimester: no known fetal harm. Third trimester: risk of maternal hemorrhage, which may indirectly affect fetus; use with caution.
Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use during pregnancy only if clearly needed. First trimester: minimal risk. Second and third trimesters: increased risk of bleeding, but no structural teratogenic effects reported.
Enoxaparin is excreted into breast milk in negligible amounts. The milk-to-plasma ratio is approximately 0.04. It is considered compatible with breastfeeding due to poor oral bioavailability in the infant. No adverse effects reported.
Tinzaparin is not excreted into breast milk in significant amounts due to high molecular weight. M/P ratio not established; expected to be low. Considered compatible with breastfeeding by most authorities.
Pregnancy increases plasma volume and renal clearance, leading to decreased peak anti-Xa levels and half-life. Dose adjustments may be needed to maintain therapeutic levels, especially in the third trimester. Weight-based dosing is recommended and may require upward titration. Anti-Xa monitoring is advised to guide dose adjustments. No standard fixed dose adjustment; individualize based on anti-Xa levels and clinical response.
Pregnancy may require dose adjustments due to increased plasma volume and renal clearance. Monitor anti-Xa levels if needed; adjust dose to maintain therapeutic range. No standard dosing algorithm; individualize based on weight and renal function.
Enoxaparin is a low molecular weight heparin (LMWH) preferred over unfractionated heparin for VTE prophylaxis due to predictable pharmacokinetics and no need for routine a PTT monitoring. Adjust dose for renal impairment (Cr Cl <30 m L/min). Protamine sulfate partially reverses (about 60%) its anticoagulant effect. Monitor for signs of bleeding, especially in elderly, low body weight (<45 kg), or those on antiplatelet agents. Avoid intramuscular injections. Spinal/epidural hematoma risk with neuraxial anesthesia; remove catheter at least 12 hours after last dose (24 hours if therapeutic dose).
Use anti-Xa monitoring in patients with renal impairment (Cr Cl <30 m L/min) or extremes of body weight. Innohep (tinzaparin) has a higher molecular weight than other LMWHs, leading to a longer half-life and potential for accumulation in renal failure. Avoid in patients with heparin-induced thrombocytopenia (HIT) history. Protamine sulfate partially reverses effect (up to 60%). Monitor platelets periodically due to risk of HIT.
Take exactly as prescribed; do not skip doses.,Inject subcutaneously in the fatty tissue of the abdomen, alternating sides.,Do not rub the injection site after administration.,Report any unusual bleeding or bruising, blood in urine or stool, or coughing up blood.,Avoid aspirin or NSAIDs unless directed by your doctor.,Seek immediate medical attention for severe headache, back pain, or neurological symptoms (signs of spinal hematoma).,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.,Do not stop abruptly without consulting your doctor.
Do not stop or change dose without consulting your doctor.,Report any signs of unusual bleeding or bruising, black/tarry stools, or blood in urine.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed.,Use electric razor and soft toothbrush to minimize bleeding risk.,Seek immediate medical help if you experience severe headache, vision changes, or signs of allergic reaction.,Do not rub injection site; rotate sites (abdomen, thigh, upper arm).,Keep a record of injection dates and times.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs INNOHEP, answered by our medical review team.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.. INNOHEP is a Low Molecular Weight Heparin that works by Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOXAPARIN SODIUM (PRESERVATIVE FREE) and INNOHEP depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOXAPARIN SODIUM (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.. The standard adult dose of INNOHEP is: Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOXAPARIN SODIUM (PRESERVATIVE FREE) and INNOHEP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOXAPARIN SODIUM (PRESERVATIVE FREE) is classified as Category A/B. Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no kno. INNOHEP is classified as Category C. Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.